BeOne Medicines (ONC) Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ONC Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BeOne Medicines AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$350.84 |
| 52 Week High | US$385.22 |
| 52 Week Low | US$253.95 |
| Beta | 0.52 |
| 1 Month Change | -6.31% |
| 3 Month Change | 27.06% |
| 1 Year Change | 3.86% |
| 3 Year Change | 84.28% |
| 5 Year Change | -6.98% |
| Change since IPO | 1,138.84% |
Recent News & Updates
Narrative Update • Sep 17
ONC: Hematology Strength And New Solid Tumor Data Will Shape Outlook
Analysts have raised their fair value estimate for BeOne Medicines from $344.15 to $370.00, citing recent price target increases across Wall Street that reference strong Q2 results, progress in oncology and hematology pipelines, and new FDA approvals for key therapies. Analyst Commentary Recent research activity on BeOne Medicines has been busy, with most firms reiterating positive stances after Q2 updates, pipeline progress, and new approvals.
Narrative Update • Sep 03
ONC: Oncology And Hema Pipeline Execution Into 2026 Will Drive Re Rating
BeOne Medicines’ analyst fair value estimate has been revised higher to $507.75 from $495.11, reflecting updated models that factor in recent beat and raise Q2 results, higher projected revenue growth, a slightly higher discount rate, a modestly lower profit margin assumption, and a richer future P/E expectation in line with analysts' focus on its advancing oncology and hema pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a broadly constructive tone, with multiple bullish analysts lifting price targets after the latest beat and raise Q2 results and pipeline updates.Recent updates
Narrative Update • Sep 17
ONC: Hematology Strength And New Solid Tumor Data Will Shape Outlook
Analysts have raised their fair value estimate for BeOne Medicines from $344.15 to $370.00, citing recent price target increases across Wall Street that reference strong Q2 results, progress in oncology and hematology pipelines, and new FDA approvals for key therapies. Analyst Commentary Recent research activity on BeOne Medicines has been busy, with most firms reiterating positive stances after Q2 updates, pipeline progress, and new approvals.Narrative Update • Sep 03
ONC: Oncology And Hema Pipeline Execution Into 2026 Will Drive Re Rating
BeOne Medicines’ analyst fair value estimate has been revised higher to $507.75 from $495.11, reflecting updated models that factor in recent beat and raise Q2 results, higher projected revenue growth, a slightly higher discount rate, a modestly lower profit margin assumption, and a richer future P/E expectation in line with analysts' focus on its advancing oncology and hema pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a broadly constructive tone, with multiple bullish analysts lifting price targets after the latest beat and raise Q2 results and pipeline updates.
Narrative Update • Aug 20
ONC: Hematology Pipeline And Solid Tumor Catalysts Will Drive Future Upside
BeOne Medicines' analyst fair value estimate has shifted to $433.02 from $412.35, as analysts factor in higher price targets following recent beat and raise quarters, supported by progress across both solid tumor and hematology pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with most firms adjusting price targets higher after the latest beat and raise quarter and pipeline updates.Analysis Article • Aug 12
Solid Earnings Reflect BeOne Medicines' (NASDAQ:ONC) Strength As A Business
When companies post strong earnings, the stock generally performs well, just like BeOne Medicines AG's ( NASDAQ:ONC...Narrative Update • Aug 06
ONC: Hematology Execution And 2026 Readouts Will Support Re Rating
BeOne Medicines' updated analyst price target edges higher as analysts factor in a fair value estimate moving to about $495, a slightly higher discount rate, more moderate revenue growth, improved profit margin expectations, and a lower assumed future P/E multiple following recent research updates from major firms. Analyst Commentary Recent research updates paint a constructive picture for BeOne Medicines, with several bullish analysts highlighting a mix of product execution, pipeline progress, and sector positioning as key supports for the stock's current valuation framework.Seeking Alpha • Jul 30
BeOne Medicines: Owning The Full B-Cell Treatment Sequence
Summary BeOne Medicines is transitioning from a BRUKINSA-driven story to an integrated hematology and oncology platform with multiple growth drivers. Q1 2026 results show 35.5% revenue growth, expanding margins, and rising profitability, supporting a premium valuation justified by strong operational leverage. BRUKINSA, BEQALZI, and tacabrutideg form a defensible three-asset hematology moat, while a solid-tumor pipeline and manufacturing expansion drive future diversification. Despite high concentration risk and a demanding valuation, ONC’s evolving product ecosystem and cash flow generation underpin a bullish outlook. Read the full article on Seeking AlphaNarrative Update • Jul 13
ONC: Hematology Leadership And Solid Tumor Data Will Drive Future Upside
Analysts have nudged their fair value estimate for BeOne Medicines higher from $336.98 to $344.15, reflecting updated assumptions around revenue growth, profit margins, and Brukinsa and pipeline momentum cited in recent price target increases across the Street. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive stance, with several firms lifting price targets in conjunction with sector-wide optimism around biotech earnings and deal activity.Narrative Update • Jun 24
ONC: Hematology Data And Solid Tumor Readouts Will Drive Future Upside
Analysts have nudged their average price targets higher for BeOne Medicines, pointing to recent FDA progress on sonrotoclax and encouraging ASCO solid tumor data as key reasons for modestly higher fair value estimates and slightly adjusted assumptions on growth, margins and future P/E. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with several bullish analysts adjusting their models after new clinical data and the FDA decision on sonrotoclax.Narrative Update • Jun 06
ONC: Hematology Leadership And Solid Tumor Pipeline Will Drive Future Upside
Analysts have nudged the fair value estimate for BeOne Medicines to about $337 per share, citing higher price targets from several firms as they factor in the recent accelerated approval of sonrotoclax and updated views on the company’s solid tumor pipeline. Analyst Commentary Recent research on BeOne Medicines reflects a mixed set of views.Narrative Update • May 23
ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside
Analysts lifted the price target on BeOne Medicines by $3 to $411.51, as updated models reflect the recent FDA accelerated approval for sonrotoclax in relapse and refractory mantle cell lymphoma, along with ongoing combination trials and a higher assumed profit margin that more than offsets slightly lower projected revenue growth and a reduced future P/E multiple. Analyst Commentary Recent research on BeOne Medicines centers on how the first FDA accelerated approval for sonrotoclax and the outlook for Brukinsa affect valuation, growth expectations, and perceived execution risk.Analysis Article • May 08
Results: BeOne Medicines AG Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, BeOne Medicines AG ( NASDAQ:ONC ) just kicked off its latest quarterly results with some very strong...Narrative Update • Apr 30
ONC: Hematology Leadership And 2026 Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target reflects a modest adjustment, with fair value moving by about $1 per share as analysts balance slightly higher revenue and profit margin assumptions with a lower future P/E multiple following recent target changes and mixed rating updates across the Street. Analyst Commentary Recent research updates on BeOne Medicines show a mix of views, but there is a clear cluster of bullish analysts who see support for the current valuation and room for further upside based on execution around core products and the pipeline.Narrative Update • Apr 16
ONC: Hematology Strength And Slower Pipeline Progress Will Shape Fairly Valued Shares
The updated analyst price target for BeOne Medicines shifts to $336 from $321, as analysts factor in slightly higher modeled revenue growth, profit margins, and future P/E assumptions, alongside mixed recent research that includes both trims and increases in published targets. Analyst Commentary Recent research around BeOne Medicines reflects a mix of enthusiasm for its core hematology asset and a more cautious reset on what investors should pay for that story.Narrative Update • Apr 02
ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside
BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.Narrative Update • Mar 19
ONC: Hematology Franchise Strength And Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target has moved lower, reflecting a reduced fair value estimate to $478.80 as analysts factor in more moderate revenue growth, slimmer profit margins, a slightly higher discount rate, and a higher future P/E multiple. This multiple is anchored by strong Brukinsa performance but a slower build for the next wave of assets.Narrative Update • Mar 04
ONC: Brukinsa Reliance And Hematology Pipeline Will Shape Fairly Valued Shares
The analyst price target for BeOne Medicines has been nudged higher by about $13 to align with a fair value update to roughly $321. Analysts are factoring in Q4 results, ongoing Brukinsa performance, and a higher future P/E assumption, alongside slightly more conservative revenue growth and profit margin inputs.Narrative Update • Feb 18
ONC: Hematology Pipeline Hype Will Pressure Shares If Execution Slips
Analysts have raised their price targets on BeOne Medicines by $9, citing a pipeline they view as underappreciated by the market and supporting that view with updated assumptions regarding growth, profitability, and valuation multiples. Analyst Commentary Recent research has centered on how fully the market is pricing BeOne Medicines' drug pipeline and long term earnings power into the current share price.Narrative Update • Feb 04
ONC: Hematology And Solid Tumor Pipeline Progress Will Drive Future Upside
Analysts lifted their price target for BeOne Medicines to about $404, up roughly $3, citing increased conviction in the value of its hematology and solid tumor pipeline, which is reflected in a slightly higher assumed future P/E multiple. Analyst Commentary Recent research updates on BeOne Medicines cluster around a similar theme: bullish analysts are raising price targets and citing comfort with both the hematology and solid tumor franchises, while also highlighting execution risks that investors should keep in mind.Narrative Update • Jan 21
ONC: Hematology Franchise And Oncology Pipeline Are Expected To Re Rate Shares
Analysts have lifted their price targets on BeOne Medicines into the low US$400s, and our fair value estimate has edged up to about US$508 as they highlight what they see as underappreciation of the pipeline, the potential for best in class hematology assets, and additional upside from oncology trial updates. Analyst Commentary Recent Street research on BeOne Medicines has tilted clearly positive, with a series of price target increases into the low US$400s range and at least one rating upgrade.Narrative Update • Jan 07
ONC: Fair View Balances Blood Cancer Progress With Gastroesophageal Cancer Opportunity
The analyst price target for BeOne Medicines has moved higher to reflect a fair value estimate of $292.03, with analysts pointing to stronger modeled revenue growth and profit margins, supported by recent Street research around Brukinsa performance, Ziihera phase III progress in HER2-positive GEA with Tevimbra, and continued confidence in the CLL and solid tumor pipeline. Analyst Commentary Recent Street research on BeOne Medicines has generally pointed to constructive views on the company’s core franchises, with several price targets adjusted higher alongside updates on Brukinsa, sonrotoclax, and the broader CLL and solid tumor pipeline.Narrative Update • Dec 14
ONC: Priority Review And Trial Progress Will Drive Future Upside Momentum
Analysts have nudged their blended price target for BeOne Medicines up by about $3 to roughly $402, citing stronger confidence in the chronic lymphocytic leukemia and solid tumor pipelines, recent Ziihera and Tevimbra data, and repeated quarterly beats that support steadily improving margins despite a slightly higher discount rate. Analyst Commentary Bullish analysts point to a broad set of recent price target hikes in the high $380s to low $420s range as evidence that the market is re-rating BeOne Medicines higher on both execution and pipeline visibility.Narrative Update • Nov 29
ONC: Priority Review And Trial Updates Will Drive Momentum Amid Sector Risks
BeOne Medicines’ analyst price target has edged up from $395 to $399, as analysts point to key clinical updates and solid quarterly performance as catalysts for incremental upside. Analyst Commentary Recent research notes from Street analysts highlight both strengths and risks for BeOne Medicines as the company navigates pivotal clinical developments and posts strong financial results.Narrative Update • Nov 15
ONC: Pipeline Data And Conference Updates Will Shape Outlook Amid Sector Risks
Analysts have increased their fair value estimate for BeOne Medicines to $395.37 from $382.29, citing strong quarterly results as well as an improved outlook for key therapies and pipeline advancements. Analyst Commentary Bullish analysts emphasized several positive trends in BeOne Medicines' recent performance and outlook, resulting in a series of raised price targets and continued positive ratings.Analysis Article • Nov 14
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve
Even though BeOne Medicines AG's ( NASDAQ:ONC ) recent earnings release was robust, the market didn't seem to notice...Narrative Update • Nov 01
ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum
BeOne Medicines' fair value price target has risen modestly by $1.20 to $382.29. Analysts cite increased confidence in peak sales for sonrotoclax and the company's broadly advancing oncology pipeline as key drivers for the upward adjustment.Narrative Update • Oct 17
Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have raised their fair value price target for BeOne Medicines from $372.97 to $381.09. They cite accelerating revenue growth, an improved profit margin outlook, and positive pivotal trial catalysts as reasons for their more optimistic projections.Narrative Update • Oct 03
Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have increased their fair value price target for BeOne Medicines by approximately $5 to $372.97. They cite robust Q2 sales growth, encouraging pipeline developments, and upward revisions to revenue forecasts as reasons for the adjustment.Narrative Update • Sep 18
Oncology Trials And Global Expansion Will Unlock Future Markets
BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.Narrative Update • Sep 03
Oncology Trials And Global Expansion Will Unlock Future Markets
The consensus analyst price target for BeOne Medicines was raised to $363.30, primarily driven by strong Brukinsa Q2 sales, improved forward revenue guidance, and ongoing pipeline progress. Analyst Commentary Bullish analysts cite robust Q2 sales growth, particularly from Brukinsa in the US and EU, as the main driver for upward price target revisions.Narrative Update • Aug 08
Oncology Trials And Global Expansion Will Unlock Future Markets
With both revenue growth and net profit margin expectations remaining essentially unchanged, analysts have maintained BeOne Medicines’ fair value at a consensus price target of $357.18. What's in the News BeOne Medicines raised 2025 revenue guidance to $5.0–$5.3 billion, now expecting positive GAAP operating income.Shareholder Returns
| ONC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | 0.3% | -0.1% |
| 1Y | 3.9% | 36.3% | 11.9% |
Return vs Industry: ONC underperformed the US Biotechs industry which returned 36.3% over the past year.
Return vs Market: ONC underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ONC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ONC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 12,000 | John Oyler | beonemedicines.com |
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
BeOne Medicines AG Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | US$39.89b |
| Earnings (TTM) | US$655.71m |
| Revenue (TTM) | US$6.13b |
60.8x
P/E Ratio6.5x
P/S RatioIs ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | US$6.13b |
| Cost of Revenue | US$680.68m |
| Gross Profit | US$5.45b |
| Other Expenses | US$4.79b |
| Earnings | US$655.71m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.77 |
| Gross Margin | 88.89% |
| Net Profit Margin | 10.70% |
| Debt/Equity Ratio | 38.3% |
How did ONC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 17:29 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeOne Medicines AG is covered by 71 analysts. 34 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tianli Wen | Aletheia Analyst Network Limited |
| Brian Skorney | Baird |
| Huidong Wang | Barclays |